Glutamate oxaloacetate transaminase
(E. coli

High purity Glutamate oxaloacetate transaminase (Escherichia coli) for use in research, biochemical enzyme assays and in vitro diagnostic analysis.

CAS: 9000-97-9

aspartate transaminase; L-aspartate:2-oxoglutarate aminotransferase

Recombinant. Highly purified. From Escherichia coliElectrophoretically homogeneous.
In 3.2 M ammonium sulphate. 
Supplied at ~ 2,500 U/mL. 

Specific activity:
~ 200 U/mg (25oC, pH 8.5 on α-ketoglutaric acid).

Stability: > 4 years at 4oC.

Product Code
5,000 Units

In association with DHL Express Megazyme offers expedited same day shipping on all orders received before 12 noon GMT, DHL offers express shipping to over 220 countries worldwide serving 35 countries next day and 65 within 2 days. For further details visit our delivery page. Should delivery error or damage require you to return a product please contact our Customer Service team to obtain shipping instructions and authorisation. For full terms and conditions see T&Cs.

We support the following payment methods:

  • Visa
  • MasterCard
  • American Express
  • Cheque
  • Wire Transfer / EFT /ACH

For further details visit our payment page


Glutamate oxaloacetate transaminase (Escherichia coli)

CAS: 9000-97-9

aspartate transaminase; L-aspartate:2-oxoglutarate aminotransferase

In 3.2 M ammonium sulphate.

> 4 years at 4oC.

Specific activity:
~ 200 U/mg (25oC, pH 8.5 on α-ketoglutaric acid).

Unit definition:
One Unit of L-glutamic-oxaloacetic transaminase activity is defined as the amount of enzyme required to convert one μmole of α-ketoglutarate to L-glutamate per minute in the presence of NADH at pH 8.5 and 25oC.

Catalyzes the reversible transfer of an α-amino group between aspartate and glutamate.

Applications in diagnostics and analytical methods in the food and feeds, fermentation, beverages and wine industries. 

Targeting glutamatergic and cellular prion protein mechanisms of amyloid β-mediated persistent synaptic plasticity disruption: Longitudinal studies.

Zhang, D., Qi, Y., Klyubin, I., Ondrejcak, T., Sarell, C. J., Cuello, A. C., Collinge, J. & Rowan, M. J. (2017). Neuropharmacology, 121, 231-246.